{
  "drugs": {
    "warfarin": {
      "drug_id": "warfarin",
      "name": "warfarin",
      "brand_names": ["Coumadin", "Jantoven"],
      "drug_class": "Anticoagulant (Vitamin K antagonist)",
      "mechanism": "Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X).",
      "indications": ["Atrial fibrillation", "Deep vein thrombosis", "Pulmonary embolism", "Mechanical heart valve"],
      "contraindications": ["Active major bleeding", "Pregnancy", "Severe hepatic disease"],
      "common_side_effects": ["Bleeding", "Bruising", "Nausea"],
      "serious_side_effects": ["Major hemorrhage", "Skin necrosis", "Purple toe syndrome"],
      "dosage_forms": ["Tablet"],
      "typical_dosage": "2-10 mg daily, adjusted by INR",
      "renal_adjustment": "Use with caution; bleeding risk increases with renal impairment.",
      "hepatic_adjustment": "Contraindicated in severe hepatic disease; enhanced anticoagulant effect.",
      "pregnancy_category": "X",
      "metabolism": "CYP2C9, CYP3A4, CYP1A2",
      "half_life": "20-60 hours (mean ~40 hours)"
    },
    "aspirin": {
      "drug_id": "aspirin",
      "name": "aspirin",
      "brand_names": ["Bayer", "Ecotrin"],
      "drug_class": "NSAID / Antiplatelet",
      "mechanism": "Irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing thromboxane A2 and prostaglandin synthesis.",
      "indications": ["Pain", "Fever", "Inflammation", "Antiplatelet therapy (MI, stroke prevention)"],
      "contraindications": ["Active peptic ulcer", "Aspirin-sensitive asthma", "Children with viral illness (Reye syndrome)"],
      "common_side_effects": ["GI upset", "Heartburn", "Nausea"],
      "serious_side_effects": ["GI bleeding", "Hemorrhagic stroke", "Reye syndrome in children"],
      "dosage_forms": ["Tablet", "Chewable tablet", "Suppository"],
      "typical_dosage": "81-325 mg daily (antiplatelet); 325-650 mg q4-6h (analgesic)",
      "renal_adjustment": "Avoid in severe renal impairment (GFR <10).",
      "hepatic_adjustment": "Avoid in severe hepatic disease.",
      "pregnancy_category": "D (3rd trimester)",
      "metabolism": "Hepatic esterases, then CYP2C9 for salicylate",
      "half_life": "15-20 minutes (aspirin); 2-30 hours (salicylate, dose-dependent)"
    },
    "fluoxetine": {
      "drug_id": "fluoxetine",
      "name": "fluoxetine",
      "brand_names": ["Prozac", "Sarafem"],
      "drug_class": "SSRI (Selective Serotonin Reuptake Inhibitor)",
      "mechanism": "Selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.",
      "indications": ["Major depressive disorder", "OCD", "Bulimia nervosa", "Panic disorder"],
      "contraindications": ["MAO inhibitor use within 14 days", "Pimozide use", "Thioridazine use"],
      "common_side_effects": ["Nausea", "Headache", "Insomnia", "Anxiety", "Sexual dysfunction"],
      "serious_side_effects": ["Serotonin syndrome", "Suicidal ideation (young adults)", "QT prolongation"],
      "dosage_forms": ["Capsule", "Tablet", "Oral solution"],
      "typical_dosage": "20-80 mg daily",
      "renal_adjustment": "No major adjustment needed.",
      "hepatic_adjustment": "Reduce dose in hepatic impairment; use lower starting dose.",
      "pregnancy_category": "C",
      "metabolism": "CYP2D6, CYP2C9",
      "half_life": "1-3 days (fluoxetine); 4-16 days (norfluoxetine)"
    },
    "tramadol": {
      "drug_id": "tramadol",
      "name": "tramadol",
      "brand_names": ["Ultram", "ConZip"],
      "drug_class": "Opioid analgesic (atypical)",
      "mechanism": "Binds mu-opioid receptors and inhibits reuptake of serotonin and norepinephrine. Active metabolite (M1) has higher mu-opioid affinity.",
      "indications": ["Moderate to moderately severe pain"],
      "contraindications": ["Seizure disorders", "Concurrent MAOIs", "Acute intoxication with alcohol/sedatives"],
      "common_side_effects": ["Nausea", "Dizziness", "Constipation", "Headache", "Drowsiness"],
      "serious_side_effects": ["Seizures", "Serotonin syndrome", "Respiratory depression", "Physical dependence"],
      "dosage_forms": ["Tablet", "Extended-release tablet"],
      "typical_dosage": "50-100 mg q4-6h (max 400 mg/day)",
      "renal_adjustment": "Reduce dose; CrCl <30: max 200 mg/day, increase interval.",
      "hepatic_adjustment": "Reduce dose in cirrhosis; 50 mg q12h.",
      "pregnancy_category": "C",
      "metabolism": "CYP2D6, CYP3A4",
      "half_life": "5-6 hours (tramadol); 7 hours (M1 metabolite)"
    },
    "metformin": {
      "drug_id": "metformin",
      "name": "metformin",
      "brand_names": ["Glucophage", "Fortamet"],
      "drug_class": "Biguanide (Antidiabetic)",
      "mechanism": "Decreases hepatic glucose production, decreases intestinal absorption of glucose, improves insulin sensitivity.",
      "indications": ["Type 2 diabetes mellitus"],
      "contraindications": ["Severe renal impairment (eGFR <30)", "Metabolic acidosis", "Conditions predisposing to lactic acidosis"],
      "common_side_effects": ["Nausea", "Diarrhea", "Abdominal pain", "Metallic taste"],
      "serious_side_effects": ["Lactic acidosis (rare)", "Vitamin B12 deficiency (long-term)"],
      "dosage_forms": ["Tablet", "Extended-release tablet", "Oral solution"],
      "typical_dosage": "500 mg BID to 1000 mg BID (max 2550 mg/day)",
      "renal_adjustment": "eGFR 30-45: max 1000 mg/day; eGFR <30: contraindicated.",
      "hepatic_adjustment": "Avoid in hepatic impairment (risk of lactic acidosis).",
      "pregnancy_category": "B",
      "metabolism": "Not metabolized; renally excreted unchanged",
      "half_life": "4-8.7 hours"
    },
    "lisinopril": {
      "drug_id": "lisinopril",
      "name": "lisinopril",
      "brand_names": ["Zestril", "Prinivil"],
      "drug_class": "ACE Inhibitor",
      "mechanism": "Inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, reducing aldosterone secretion.",
      "indications": ["Hypertension", "Heart failure", "Post-MI", "Diabetic nephropathy"],
      "contraindications": ["Bilateral renal artery stenosis", "History of ACE-inhibitor angioedema", "Pregnancy"],
      "common_side_effects": ["Dry cough", "Dizziness", "Headache", "Hyperkalemia"],
      "serious_side_effects": ["Angioedema", "Renal failure", "Severe hyperkalemia"],
      "dosage_forms": ["Tablet"],
      "typical_dosage": "10-40 mg daily",
      "renal_adjustment": "CrCl 10-30: reduce initial dose to 5 mg; CrCl <10: 2.5 mg.",
      "hepatic_adjustment": "No specific adjustment.",
      "pregnancy_category": "D",
      "metabolism": "Not metabolized; renally excreted unchanged",
      "half_life": "12 hours"
    },
    "spironolactone": {
      "drug_id": "spironolactone",
      "name": "spironolactone",
      "brand_names": ["Aldactone"],
      "drug_class": "Potassium-sparing diuretic / Aldosterone antagonist",
      "mechanism": "Competitively blocks aldosterone receptors in the distal tubule, promoting sodium excretion and potassium retention.",
      "indications": ["Heart failure", "Ascites (cirrhosis)", "Hypertension", "Primary hyperaldosteronism"],
      "contraindications": ["Hyperkalemia", "Anuria", "Addison disease"],
      "common_side_effects": ["Hyperkalemia", "Gynecomastia", "GI upset", "Dizziness"],
      "serious_side_effects": ["Severe hyperkalemia", "Metabolic acidosis", "Agranulocytosis"],
      "dosage_forms": ["Tablet"],
      "typical_dosage": "25-200 mg daily",
      "renal_adjustment": "Use with extreme caution in renal impairment; monitor potassium closely.",
      "hepatic_adjustment": "Often used for hepatic ascites; titrate carefully.",
      "pregnancy_category": "C",
      "metabolism": "CYP2C8, CYP3A4 to active metabolites (canrenone)",
      "half_life": "1.4 hours (spironolactone); 10-35 hours (canrenone)"
    },
    "phenytoin": {
      "drug_id": "phenytoin",
      "name": "phenytoin",
      "brand_names": ["Dilantin", "Phenytek"],
      "drug_class": "Anticonvulsant (Hydantoin)",
      "mechanism": "Stabilizes neuronal membranes by blocking voltage-gated sodium channels, reducing repetitive firing.",
      "indications": ["Epilepsy (tonic-clonic, partial seizures)", "Status epilepticus", "Cardiac arrhythmias"],
      "contraindications": ["Sinus bradycardia", "SA/AV block", "Adams-Stokes syndrome"],
      "common_side_effects": ["Nystagmus", "Ataxia", "Gingival hyperplasia", "Hirsutism"],
      "serious_side_effects": ["Stevens-Johnson syndrome", "Hepatotoxicity", "Aplastic anemia", "Cardiac arrhythmias (IV)"],
      "dosage_forms": ["Capsule", "Oral suspension", "IV injection"],
      "typical_dosage": "300-400 mg daily in divided doses; target level 10-20 mcg/mL",
      "renal_adjustment": "Unbound fraction increases in renal failure; monitor free levels.",
      "hepatic_adjustment": "Reduced metabolism; use lower doses and monitor closely.",
      "pregnancy_category": "D",
      "metabolism": "CYP2C9, CYP2C19 (saturable kinetics)",
      "half_life": "7-42 hours (dose-dependent, nonlinear kinetics)"
    },
    "simvastatin": {
      "drug_id": "simvastatin",
      "name": "simvastatin",
      "brand_names": ["Zocor"],
      "drug_class": "Statin (HMG-CoA reductase inhibitor)",
      "mechanism": "Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, upregulating LDL receptors.",
      "indications": ["Hypercholesterolemia", "Cardiovascular risk reduction"],
      "contraindications": ["Active liver disease", "Pregnancy", "Concurrent strong CYP3A4 inhibitors at high doses"],
      "common_side_effects": ["Myalgia", "Headache", "GI upset", "Elevated transaminases"],
      "serious_side_effects": ["Rhabdomyolysis", "Hepatotoxicity", "Myopathy"],
      "dosage_forms": ["Tablet"],
      "typical_dosage": "10-40 mg daily (max 80 mg only for established patients)",
      "renal_adjustment": "Start at 5 mg for severe renal impairment.",
      "hepatic_adjustment": "Contraindicated in active liver disease.",
      "pregnancy_category": "X",
      "metabolism": "CYP3A4",
      "half_life": "1.9 hours (simvastatin); longer for active metabolites"
    },
    "amiodarone": {
      "drug_id": "amiodarone",
      "name": "amiodarone",
      "brand_names": ["Cordarone", "Pacerone"],
      "drug_class": "Class III Antiarrhythmic",
      "mechanism": "Blocks potassium channels (prolongs repolarization), also blocks sodium and calcium channels, and has anti-adrenergic properties.",
      "indications": ["Ventricular arrhythmias", "Atrial fibrillation (rhythm control)"],
      "contraindications": ["Severe sinus node dysfunction", "2nd/3rd degree AV block", "Cardiogenic shock"],
      "common_side_effects": ["Photosensitivity", "Thyroid dysfunction", "Corneal microdeposits", "Tremor"],
      "serious_side_effects": ["Pulmonary toxicity", "Hepatotoxicity", "Thyrotoxicosis", "Peripheral neuropathy", "QT prolongation / Torsades"],
      "dosage_forms": ["Tablet", "IV injection"],
      "typical_dosage": "Loading: 800-1600 mg/day for 1-3 weeks; Maintenance: 200-400 mg/day",
      "renal_adjustment": "No specific adjustment (not renally excreted).",
      "hepatic_adjustment": "Use with caution; can cause hepatotoxicity.",
      "pregnancy_category": "D",
      "metabolism": "CYP3A4, CYP2C8 (also a potent inhibitor of CYP2D6, CYP3A4, CYP2C9)",
      "half_life": "40-55 days (extremely long)"
    },
    "clopidogrel": {
      "drug_id": "clopidogrel",
      "name": "clopidogrel",
      "brand_names": ["Plavix"],
      "drug_class": "Antiplatelet (P2Y12 inhibitor)",
      "mechanism": "Prodrug; active metabolite irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet aggregation.",
      "indications": ["Acute coronary syndrome", "Stroke prevention", "Peripheral arterial disease", "PCI stent thrombosis prevention"],
      "contraindications": ["Active pathological bleeding"],
      "common_side_effects": ["Bleeding", "Bruising", "GI upset", "Headache"],
      "serious_side_effects": ["Major hemorrhage", "TTP (thrombotic thrombocytopenic purpura)", "Neutropenia"],
      "dosage_forms": ["Tablet"],
      "typical_dosage": "75 mg daily (loading dose: 300-600 mg)",
      "renal_adjustment": "No adjustment needed.",
      "hepatic_adjustment": "Use with caution in severe hepatic impairment (reduced activation).",
      "pregnancy_category": "B",
      "metabolism": "CYP2C19 (primary), CYP3A4, CYP1A2",
      "half_life": "6 hours (parent); active metabolite acts irreversibly"
    },
    "omeprazole": {
      "drug_id": "omeprazole",
      "name": "omeprazole",
      "brand_names": ["Prilosec"],
      "drug_class": "Proton Pump Inhibitor (PPI)",
      "mechanism": "Irreversibly inhibits the H+/K+ ATPase proton pump in gastric parietal cells, reducing acid secretion.",
      "indications": ["GERD", "Peptic ulcer disease", "H. pylori eradication (combination)", "Zollinger-Ellison syndrome"],
      "contraindications": ["Hypersensitivity to PPIs", "Concurrent rilpivirine use"],
      "common_side_effects": ["Headache", "Nausea", "Diarrhea", "Abdominal pain"],
      "serious_side_effects": ["C. difficile infection", "Hypomagnesemia", "Bone fractures (long-term)", "Vitamin B12 deficiency"],
      "dosage_forms": ["Capsule", "Oral suspension", "IV injection"],
      "typical_dosage": "20-40 mg daily",
      "renal_adjustment": "No adjustment needed.",
      "hepatic_adjustment": "Max 20 mg/day in severe hepatic impairment.",
      "pregnancy_category": "C",
      "metabolism": "CYP2C19, CYP3A4 (omeprazole is also a CYP2C19 inhibitor)",
      "half_life": "0.5-1 hour"
    },
    "contrast_dye": {
      "drug_id": "contrast_dye",
      "name": "contrast_dye",
      "brand_names": ["Omnipaque (iohexol)", "Isovue (iopamidol)", "Visipaque (iodixanol)", "Optiray (ioversol)"],
      "drug_class": "Iodinated Contrast Media",
      "mechanism": "Contains iodine atoms that attenuate X-rays, providing radiographic contrast for vascular structures, organs, and tissues during CT, angiography, and other imaging procedures.",
      "indications": ["CT contrast enhancement", "Coronary angiography", "Urography", "Myelography", "Peripheral angiography"],
      "contraindications": ["Severe iodine allergy (relative)", "Severe renal impairment (relative)", "Thyrotoxicosis (iodine load risk)", "Pheochromocytoma (hypertensive crisis risk)"],
      "common_side_effects": ["Warmth/flushing sensation", "Metallic taste", "Nausea", "Headache", "Injection site pain"],
      "serious_side_effects": ["Anaphylactoid reaction", "Contrast-induced nephropathy (CIN)", "Cardiac arrhythmias", "Pulmonary edema", "Seizures"],
      "dosage_forms": ["IV injection", "Intra-arterial injection", "Intrathecal injection"],
      "typical_dosage": "Variable by procedure; CT: 50-150 mL IV of 300-370 mgI/mL concentration",
      "renal_adjustment": "Use lowest effective dose; ensure adequate hydration. eGFR <30: avoid if possible or use with aggressive IV hydration protocol.",
      "hepatic_adjustment": "No specific adjustment; primarily renally excreted.",
      "pregnancy_category": "B",
      "metabolism": "Not metabolized; excreted unchanged by glomerular filtration",
      "half_life": "1-2 hours (normal renal function); significantly prolonged in renal impairment"
    },
    "methotrexate": {
      "drug_id": "methotrexate",
      "name": "methotrexate",
      "brand_names": ["Trexall", "Rheumatrex", "Otrexup", "Rasuvo"],
      "drug_class": "Antimetabolite / Disease-modifying antirheumatic drug (DMARD)",
      "mechanism": "Inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate, thereby impairing purine and thymidylate synthesis. At low doses (RA), also increases adenosine release, mediating anti-inflammatory effects.",
      "indications": ["Rheumatoid arthritis", "Psoriasis", "Acute lymphoblastic leukemia", "Ectopic pregnancy", "Crohn disease (off-label)"],
      "contraindications": ["Pregnancy", "Breastfeeding", "Severe hepatic impairment", "Severe renal impairment (CrCl <30)", "Pre-existing blood dyscrasias", "Active infection", "Immunodeficiency syndromes"],
      "common_side_effects": ["Nausea", "Stomatitis", "Fatigue", "Elevated transaminases", "Anorexia", "Diarrhea"],
      "serious_side_effects": ["Pancytopenia / bone marrow suppression", "Hepatotoxicity / cirrhosis (long-term)", "Pneumonitis", "Nephrotoxicity", "Severe mucositis", "Tumor lysis syndrome (oncology doses)"],
      "dosage_forms": ["Tablet", "Subcutaneous injection", "Intramuscular injection", "IV injection", "Intrathecal injection"],
      "typical_dosage": "RA: 7.5-25 mg once weekly; Oncology: varies widely by protocol (up to g/m² doses)",
      "renal_adjustment": "CrCl 10-50: reduce dose by 50%; CrCl <10: avoid use. Methotrexate is primarily renally excreted; impaired clearance greatly increases toxicity risk.",
      "hepatic_adjustment": "Avoid or use with extreme caution in hepatic impairment; monitor LFTs closely. Contraindicated if bilirubin >5 mg/dL.",
      "pregnancy_category": "X",
      "metabolism": "Intracellular polyglutamation; hepatic aldehyde oxidase converts to 7-hydroxymethotrexate. Primarily renally excreted (80-90% unchanged).",
      "half_life": "3-10 hours (low dose); 8-15 hours (high dose). Terminal phase may extend to 27 hours."
    },
    "NSAIDs": {
      "drug_id": "NSAIDs",
      "name": "NSAIDs (class: ibuprofen/naproxen)",
      "brand_names": ["Advil (ibuprofen)", "Motrin (ibuprofen)", "Aleve (naproxen)", "Naprosyn (naproxen)"],
      "drug_class": "Non-Steroidal Anti-Inflammatory Drug (NSAID)",
      "mechanism": "Reversibly inhibits cyclooxygenase enzymes COX-1 and COX-2, reducing prostaglandin synthesis. This decreases inflammation, pain, and fever. Also reduces renal prostaglandin-mediated vasodilation, which can impair renal blood flow.",
      "indications": ["Pain (mild to moderate)", "Inflammation", "Fever", "Osteoarthritis", "Rheumatoid arthritis", "Dysmenorrhea", "Gout (acute)"],
      "contraindications": ["Active GI bleeding or peptic ulcer", "Severe renal impairment", "Third trimester of pregnancy", "History of NSAID-induced asthma/urticaria", "Post-CABG surgery"],
      "common_side_effects": ["GI upset", "Dyspepsia", "Nausea", "Headache", "Dizziness", "Fluid retention"],
      "serious_side_effects": ["GI bleeding / perforation", "Acute kidney injury", "Cardiovascular events (MI, stroke)", "Stevens-Johnson syndrome", "Hepatotoxicity", "Severe allergic reactions"],
      "dosage_forms": ["Tablet", "Capsule", "Oral suspension", "Topical gel"],
      "typical_dosage": "Ibuprofen: 200-800 mg q6-8h (max 3200 mg/day); Naproxen: 250-500 mg q12h (max 1250 mg/day)",
      "renal_adjustment": "Avoid in severe renal impairment. Use lowest effective dose for shortest duration in mild-moderate renal impairment; monitor renal function.",
      "hepatic_adjustment": "Use with caution in hepatic impairment; avoid in severe liver disease.",
      "pregnancy_category": "C (1st/2nd trimester); D (3rd trimester)",
      "metabolism": "Hepatic via CYP2C9 (major), CYP2C8. Extensively metabolized to inactive metabolites.",
      "half_life": "Ibuprofen: 1.8-2 hours; Naproxen: 12-17 hours"
    },
    "ciprofloxacin": {
      "drug_id": "ciprofloxacin",
      "name": "ciprofloxacin",
      "brand_names": ["Cipro", "Cipro XR"],
      "drug_class": "Fluoroquinolone Antibiotic",
      "mechanism": "Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination. Bactericidal.",
      "indications": ["Urinary tract infections", "Respiratory tract infections", "Intra-abdominal infections", "Bone and joint infections", "Anthrax prophylaxis/treatment", "Infectious diarrhea"],
      "contraindications": ["Concurrent tizanidine use", "History of tendon disorders with fluoroquinolone use", "Myasthenia gravis (may worsen)"],
      "common_side_effects": ["Nausea", "Diarrhea", "Headache", "Dizziness", "Rash", "Abdominal pain"],
      "serious_side_effects": ["Tendon rupture (especially Achilles)", "Peripheral neuropathy", "CNS effects (seizures, psychosis)", "QT prolongation", "C. difficile colitis", "Aortic aneurysm/dissection"],
      "dosage_forms": ["Tablet", "Extended-release tablet", "Oral suspension", "IV injection", "Ophthalmic drops", "Otic drops"],
      "typical_dosage": "250-750 mg PO q12h; 200-400 mg IV q8-12h (depending on infection severity)",
      "renal_adjustment": "CrCl 30-50: no change for most indications. CrCl 5-29: 250-500 mg q18h. Hemodialysis: 250-500 mg q24h (after dialysis).",
      "hepatic_adjustment": "No specific adjustment; use with caution in severe hepatic insufficiency.",
      "pregnancy_category": "C",
      "metabolism": "Partially hepatic (CYP1A2 minor); 40-50% excreted unchanged renally. Ciprofloxacin is a potent inhibitor of CYP1A2.",
      "half_life": "4-6 hours (normal renal function); prolonged in renal impairment"
    },
    "theophylline": {
      "drug_id": "theophylline",
      "name": "theophylline",
      "brand_names": ["Theo-24", "Elixophyllin", "Theochron"],
      "drug_class": "Methylxanthine Bronchodilator",
      "mechanism": "Non-selective phosphodiesterase inhibitor that increases intracellular cAMP, causing bronchial smooth muscle relaxation. Also antagonizes adenosine receptors, stimulates respiratory drive, and has mild anti-inflammatory and immunomodulatory effects.",
      "indications": ["Asthma (adjunct therapy)", "COPD", "Neonatal apnea"],
      "contraindications": ["Uncontrolled arrhythmias", "Active peptic ulcer disease", "Seizure disorder (relative)"],
      "common_side_effects": ["Nausea", "Vomiting", "Headache", "Insomnia", "Restlessness", "Tremor", "Tachycardia"],
      "serious_side_effects": ["Seizures", "Cardiac arrhythmias (ventricular tachycardia, atrial fibrillation)", "GI hemorrhage", "Sudden death (at very high levels)"],
      "dosage_forms": ["Tablet", "Extended-release tablet", "Capsule", "Oral solution", "IV injection (aminophylline)"],
      "typical_dosage": "300-600 mg/day in divided doses (immediate release) or once daily (extended release); target serum level 5-15 mcg/mL",
      "renal_adjustment": "No major adjustment; metabolites accumulate but are not clinically significant.",
      "hepatic_adjustment": "Reduce dose significantly in hepatic impairment (cirrhosis, acute hepatitis); clearance may decrease by 50% or more. Monitor levels closely.",
      "pregnancy_category": "C",
      "metabolism": "Hepatic via CYP1A2 (primary), CYP2E1, CYP3A4 (minor). Narrow therapeutic index; levels highly sensitive to CYP1A2 inhibitors/inducers.",
      "half_life": "3-13 hours in adults (average ~8 hours); shorter in children, longer in elderly, CHF, liver disease, and with CYP1A2 inhibitors"
    },
    "digoxin": {
      "drug_id": "digoxin",
      "name": "digoxin",
      "brand_names": ["Lanoxin", "Digitek", "Digox"],
      "drug_class": "Cardiac Glycoside",
      "mechanism": "Inhibits the Na+/K+ ATPase pump in cardiac myocytes, increasing intracellular sodium, which enhances Na+/Ca2+ exchange and increases intracellular calcium, leading to increased cardiac contractility (positive inotropy). Also increases vagal tone, slowing AV nodal conduction (negative chronotropy/dromotropy).",
      "indications": ["Heart failure (HFrEF, symptomatic benefit)", "Atrial fibrillation (rate control)", "Atrial flutter (rate control)"],
      "contraindications": ["Ventricular fibrillation", "Hypertrophic obstructive cardiomyopathy (HOCM)", "Hypokalemia (increases toxicity risk)", "Hypercalcemia"],
      "common_side_effects": ["Nausea", "Anorexia", "Dizziness", "Visual disturbances (yellow-green halos, blurred vision)", "Fatigue"],
      "serious_side_effects": ["Cardiac arrhythmias (bradycardia, heart block, ventricular tachycardia, bigeminy)", "Digoxin toxicity syndrome", "Hyperkalemia (in acute overdose)", "Mesenteric ischemia"],
      "dosage_forms": ["Tablet", "Oral solution", "IV injection"],
      "typical_dosage": "0.125-0.25 mg daily; target serum level 0.5-2.0 ng/mL (lower target 0.5-0.9 ng/mL in HF for mortality benefit)",
      "renal_adjustment": "CrCl 10-50: reduce dose by 25-75%; CrCl <10: reduce dose by 50-75%. Primarily renally excreted; dose must be individualized based on levels.",
      "hepatic_adjustment": "No specific adjustment; not significantly hepatically metabolized.",
      "pregnancy_category": "C",
      "metabolism": "Minimal hepatic metabolism (~16%); primarily excreted unchanged by the kidneys (~60-80%). Also a substrate of P-glycoprotein (P-gp) efflux transporter.",
      "half_life": "36-48 hours (normal renal function); significantly prolonged in renal impairment (up to 4-6 days)"
    },
    "lithium": {
      "drug_id": "lithium",
      "name": "lithium",
      "brand_names": ["Lithobid", "Eskalith"],
      "drug_class": "Mood Stabilizer",
      "mechanism": "Exact mechanism not fully understood. Modulates inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), affecting intracellular signaling cascades. Alters sodium transport across neuronal membranes, modulates neurotransmitter release (serotonin, norepinephrine, dopamine), and has neuroprotective effects.",
      "indications": ["Bipolar disorder (acute mania and maintenance)", "Bipolar depression (augmentation)", "Treatment-resistant depression (augmentation)", "Schizoaffective disorder"],
      "contraindications": ["Severe renal impairment", "Severe cardiovascular disease", "Severe debilitation/dehydration/sodium depletion", "Brugada syndrome"],
      "common_side_effects": ["Tremor (fine)", "Polyuria/polydipsia (nephrogenic diabetes insipidus)", "Nausea", "Weight gain", "Hypothyroidism", "Cognitive dulling", "Diarrhea"],
      "serious_side_effects": ["Lithium toxicity (levels >1.5 mEq/L: coarse tremor, ataxia, slurred speech; >2.5 mEq/L: seizures, coma, death)", "Nephrogenic diabetes insipidus", "Chronic kidney disease (long-term)", "Cardiac conduction abnormalities (sinus node dysfunction)", "Ebstein anomaly (1st trimester exposure)"],
      "dosage_forms": ["Tablet", "Extended-release tablet", "Capsule", "Oral solution"],
      "typical_dosage": "900-1200 mg/day in 2-3 divided doses; target serum level 0.6-1.2 mEq/L (acute mania: 0.8-1.2; maintenance: 0.6-0.8)",
      "renal_adjustment": "Reduce dose proportionally to GFR decline; monitor levels frequently. Avoid if CrCl <10 mL/min. Lithium is entirely renally excreted.",
      "hepatic_adjustment": "No specific adjustment (not hepatically metabolized).",
      "pregnancy_category": "D",
      "metabolism": "Not metabolized; entirely renally excreted by glomerular filtration with ~80% reabsorbed in the proximal tubule (competes with sodium reabsorption).",
      "half_life": "18-24 hours (adults); longer in elderly and renal impairment"
    },
    "rifampin": {
      "drug_id": "rifampin",
      "name": "rifampin",
      "brand_names": ["Rifadin", "Rimactane"],
      "drug_class": "Rifamycin Antibiotic / CYP Enzyme Inducer",
      "mechanism": "Inhibits bacterial DNA-dependent RNA polymerase, blocking RNA transcription. Bactericidal against Mycobacterium tuberculosis. Also one of the most potent known inducers of multiple CYP enzymes and drug transporters.",
      "indications": ["Tuberculosis (combination therapy)", "Latent TB infection", "Staphylococcal infections (prosthetic valve endocarditis, osteomyelitis - combination)", "Meningococcal prophylaxis", "H. influenzae type b prophylaxis", "Leprosy"],
      "contraindications": ["Hypersensitivity to rifamycins", "Concurrent use with protease inhibitors (most)", "Jaundice"],
      "common_side_effects": ["Orange-red discoloration of body fluids (urine, tears, sweat)", "GI upset", "Hepatotoxicity (transaminase elevation)", "Rash", "Pruritus"],
      "serious_side_effects": ["Hepatotoxicity (hepatitis, liver failure)", "Thrombocytopenia", "Hemolytic anemia", "Acute renal failure (interstitial nephritis)", "Flu-like syndrome (intermittent dosing)"],
      "dosage_forms": ["Capsule", "IV injection"],
      "typical_dosage": "TB: 600 mg daily (10 mg/kg, max 600 mg); Latent TB: 600 mg daily for 4 months",
      "renal_adjustment": "No adjustment needed (primarily hepatically eliminated).",
      "hepatic_adjustment": "Use with extreme caution; can cause severe hepatotoxicity. Avoid in pre-existing liver disease if possible. Monitor LFTs closely.",
      "pregnancy_category": "C",
      "metabolism": "Hepatic deacetylation to desacetylrifampin (active). Potent inducer of CYP3A4, CYP2C9, CYP2C19, CYP2B6, CYP1A2, and P-glycoprotein. Undergoes enterohepatic circulation.",
      "half_life": "3-4 hours (decreases with repeated dosing due to auto-induction)"
    },
    "oral_contraceptives": {
      "drug_id": "oral_contraceptives",
      "name": "oral_contraceptives (combined estrogen/progestin)",
      "brand_names": ["Ortho Tri-Cyclen", "Yaz", "Lo Loestrin Fe", "NuvaRing (vaginal ring equivalent)"],
      "drug_class": "Combined Hormonal Contraceptive",
      "mechanism": "Combination of synthetic estrogen (ethinyl estradiol) and a progestin that suppresses ovulation by inhibiting the hypothalamic-pituitary-ovarian axis (suppressing GnRH, LH, and FSH). Also thickens cervical mucus and alters the endometrium to reduce implantation likelihood.",
      "indications": ["Contraception", "Menstrual regulation", "Dysmenorrhea", "Acne (select formulations)", "Endometriosis", "PCOS management"],
      "contraindications": ["History of VTE or PE", "Known thrombogenic mutations (e.g., Factor V Leiden)", "Smoking and age >35", "Breast cancer (current or history)", "Uncontrolled hypertension", "Migraine with aura", "Hepatic tumors", "Active liver disease"],
      "common_side_effects": ["Nausea", "Breast tenderness", "Headache", "Breakthrough bleeding", "Mood changes", "Weight gain (mild)"],
      "serious_side_effects": ["Venous thromboembolism (DVT/PE)", "Arterial thrombosis (MI, stroke)", "Hepatic adenoma", "Hypertension", "Gallbladder disease"],
      "dosage_forms": ["Tablet (21-day or 28-day packs)", "Extended-cycle tablet"],
      "typical_dosage": "One tablet daily at the same time; 21 days active + 7 days placebo (or continuous depending on regimen). Ethinyl estradiol 20-35 mcg + variable progestin.",
      "renal_adjustment": "No specific adjustment, but use with caution in renal impairment due to fluid retention.",
      "hepatic_adjustment": "Contraindicated in active liver disease, hepatic tumors, or cholestatic jaundice of pregnancy.",
      "pregnancy_category": "X",
      "metabolism": "Ethinyl estradiol: CYP3A4 (major), CYP2C9; hepatic conjugation and enterohepatic recirculation. Progestins: CYP3A4 (major). Highly susceptible to CYP3A4 inducers.",
      "half_life": "Ethinyl estradiol: 12-23 hours; Progestin: varies by type (e.g., levonorgestrel 24-32 hours, drospirenone 30 hours)"
    }
  },
  "interactions": {
    "int_warfarin_aspirin": {
      "interaction_id": "int_warfarin_aspirin",
      "drug_a": "warfarin",
      "drug_b": "aspirin",
      "severity": "major",
      "mechanism": "Aspirin inhibits platelet function (via COX-1) and can cause GI mucosal erosion. Combined with warfarin's anticoagulant effect, the risk of bleeding is significantly increased.",
      "effect": "Markedly increased risk of bleeding, especially GI hemorrhage.",
      "management": "Avoid combination if possible. If dual therapy is necessary (e.g., mechanical valve + ACS), use low-dose aspirin (81 mg), closely monitor INR, and prescribe GI protection (PPI).",
      "evidence_level": "well_established"
    },
    "int_fluoxetine_tramadol": {
      "interaction_id": "int_fluoxetine_tramadol",
      "drug_a": "fluoxetine",
      "drug_b": "tramadol",
      "severity": "major",
      "mechanism": "Both fluoxetine and tramadol increase serotonin levels. Fluoxetine also inhibits CYP2D6, which converts tramadol to its active metabolite (M1), potentially reducing analgesic efficacy while increasing serotonin toxicity risk.",
      "effect": "Increased risk of serotonin syndrome (agitation, hyperthermia, tachycardia, tremor, myoclonus, diarrhea). Also reduced tramadol analgesic effect due to CYP2D6 inhibition.",
      "management": "Avoid combination. If unavoidable, use lowest effective doses, closely monitor for signs of serotonin syndrome, and educate patient on warning signs. Consider alternative analgesic (acetaminophen, non-serotonergic opioid).",
      "evidence_level": "well_established"
    },
    "int_lisinopril_spironolactone": {
      "interaction_id": "int_lisinopril_spironolactone",
      "drug_a": "lisinopril",
      "drug_b": "spironolactone",
      "severity": "major",
      "mechanism": "ACE inhibitors reduce aldosterone secretion (increasing potassium retention). Spironolactone blocks aldosterone receptors (further increasing potassium retention). Combined effect significantly elevates serum potassium.",
      "effect": "Significant risk of hyperkalemia, which can cause cardiac arrhythmias and cardiac arrest.",
      "management": "Can be used together with careful monitoring (e.g., in heart failure with reduced EF per guidelines). Monitor potassium closely (within 1 week of initiation, then monthly). Avoid potassium supplements and salt substitutes. Start spironolactone at low dose (12.5-25 mg). Discontinue if K+ >5.5 mEq/L.",
      "evidence_level": "well_established"
    },
    "int_warfarin_fluoxetine": {
      "interaction_id": "int_warfarin_fluoxetine",
      "drug_a": "warfarin",
      "drug_b": "fluoxetine",
      "severity": "moderate",
      "mechanism": "Fluoxetine inhibits CYP2C9, which is a major metabolic pathway for warfarin's more potent S-enantiomer. SSRIs also impair platelet function by depleting platelet serotonin.",
      "effect": "Increased warfarin effect (elevated INR) and increased bleeding risk due to both pharmacokinetic and pharmacodynamic mechanisms.",
      "management": "Monitor INR closely when starting, stopping, or adjusting fluoxetine dose. May need to reduce warfarin dose by 10-30%. Consider alternative antidepressants with less CYP2C9 interaction (e.g., sertraline at low doses).",
      "evidence_level": "clinical_study"
    },
    "int_simvastatin_amiodarone": {
      "interaction_id": "int_simvastatin_amiodarone",
      "drug_a": "simvastatin",
      "drug_b": "amiodarone",
      "severity": "major",
      "mechanism": "Amiodarone is a potent inhibitor of CYP3A4, which is the primary metabolic pathway for simvastatin. This leads to dramatically increased simvastatin plasma levels.",
      "effect": "Greatly increased risk of myopathy and rhabdomyolysis due to elevated statin levels.",
      "management": "Do NOT exceed simvastatin 20 mg/day when used with amiodarone (FDA warning). Consider switching to a statin not primarily metabolized by CYP3A4 (e.g., rosuvastatin, pravastatin). Monitor for muscle pain, weakness, and CK levels.",
      "evidence_level": "well_established"
    },
    "int_clopidogrel_omeprazole": {
      "interaction_id": "int_clopidogrel_omeprazole",
      "drug_a": "clopidogrel",
      "drug_b": "omeprazole",
      "severity": "moderate",
      "mechanism": "Omeprazole inhibits CYP2C19, which is essential for converting the clopidogrel prodrug to its active metabolite. This reduces the antiplatelet effect of clopidogrel.",
      "effect": "Reduced clopidogrel antiplatelet activity, potentially increasing risk of cardiovascular events (stent thrombosis, MI, stroke).",
      "management": "Use an alternative PPI with less CYP2C19 inhibition (pantoprazole preferred). If omeprazole must be used, separate dosing times by at least 12 hours (limited evidence for benefit). Consider H2-blocker (famotidine) as alternative GI protection.",
      "evidence_level": "clinical_study"
    },
    "int_warfarin_phenytoin": {
      "interaction_id": "int_warfarin_phenytoin",
      "drug_a": "warfarin",
      "drug_b": "phenytoin",
      "severity": "major",
      "mechanism": "Complex bidirectional interaction. Initially, phenytoin may displace warfarin from protein binding (transiently increasing free warfarin). Long-term, phenytoin induces CYP enzymes that metabolize warfarin (decreasing warfarin effect). Warfarin can also inhibit phenytoin metabolism.",
      "effect": "Unpredictable changes in anticoagulant effect and phenytoin levels. Risk of both bleeding and subtherapeutic anticoagulation.",
      "management": "Monitor INR very closely (weekly) when starting/stopping/changing phenytoin dose. Monitor phenytoin levels concurrently. Dose adjustments for both drugs may be needed. Consider alternative anticonvulsants (e.g., levetiracetam) that lack CYP interactions.",
      "evidence_level": "well_established"
    },
    "int_metformin_lisinopril": {
      "interaction_id": "int_metformin_lisinopril",
      "drug_a": "metformin",
      "drug_b": "lisinopril",
      "severity": "minor",
      "mechanism": "ACE inhibitors may enhance insulin sensitivity and have a mild hypoglycemic effect. Combined with metformin, there may be a slightly increased risk of hypoglycemia, though this is uncommon.",
      "effect": "Slightly enhanced glucose-lowering effect. Generally a beneficial combination in diabetic patients with hypertension.",
      "management": "No dose adjustment typically needed. This is often a desirable combination. Monitor blood glucose if initiating ACE inhibitor in a patient on metformin.",
      "evidence_level": "clinical_study"
    },
    "int_fluoxetine_phenytoin": {
      "interaction_id": "int_fluoxetine_phenytoin",
      "drug_a": "fluoxetine",
      "drug_b": "phenytoin",
      "severity": "moderate",
      "mechanism": "Fluoxetine inhibits CYP2C9, which is a major pathway for phenytoin metabolism. This can lead to increased phenytoin levels.",
      "effect": "Elevated phenytoin levels with potential for toxicity (nystagmus, ataxia, sedation, seizures at very high levels).",
      "management": "Monitor phenytoin levels closely when starting or adjusting fluoxetine. Reduce phenytoin dose if needed. Consider alternative antidepressants with less CYP2C9 inhibition.",
      "evidence_level": "clinical_study"
    },
    "int_amiodarone_warfarin": {
      "interaction_id": "int_amiodarone_warfarin",
      "drug_a": "amiodarone",
      "drug_b": "warfarin",
      "severity": "major",
      "mechanism": "Amiodarone potently inhibits CYP2C9, CYP3A4, and CYP1A2, all of which are involved in warfarin metabolism. This interaction has a slow onset (due to amiodarone's very long half-life) and persists weeks after discontinuation.",
      "effect": "Markedly increased warfarin effect and INR, with high risk of serious bleeding.",
      "management": "Empirically reduce warfarin dose by 30-50% when initiating amiodarone. Monitor INR weekly for the first several months. Effect may not stabilize for 6-8 weeks. Continue close monitoring for weeks after amiodarone discontinuation.",
      "evidence_level": "well_established"
    },
    "int_metformin_contrast_dye": {
      "interaction_id": "int_metformin_contrast_dye",
      "drug_a": "metformin",
      "drug_b": "contrast_dye",
      "severity": "major",
      "mechanism": "Iodinated contrast media can cause contrast-induced nephropathy (CIN), leading to acute kidney injury. With impaired renal function, metformin accumulates because it is entirely renally excreted, leading to metformin-associated lactic acidosis (MALA) — a rare but life-threatening complication.",
      "effect": "Risk of lactic acidosis due to metformin accumulation secondary to contrast-induced renal impairment. Lactic acidosis has a mortality rate of approximately 50%.",
      "management": "Withhold metformin at the time of or prior to iodinated contrast administration. Hold metformin for at least 48 hours after the procedure. Reassess renal function (serum creatinine/eGFR) before restarting metformin. Ensure adequate IV hydration before and after contrast. In patients with eGFR <60 at baseline, extra caution is warranted.",
      "evidence_level": "well_established"
    },
    "int_methotrexate_NSAIDs": {
      "interaction_id": "int_methotrexate_NSAIDs",
      "drug_a": "methotrexate",
      "drug_b": "NSAIDs",
      "severity": "major",
      "mechanism": "NSAIDs reduce renal blood flow by inhibiting prostaglandin-mediated afferent arteriolar vasodilation, decreasing glomerular filtration rate. Since methotrexate is primarily renally excreted (80-90% unchanged), reduced clearance leads to methotrexate accumulation. NSAIDs may also displace methotrexate from plasma protein binding sites and inhibit tubular secretion of methotrexate.",
      "effect": "Increased methotrexate serum levels and prolonged exposure, significantly elevating the risk of methotrexate toxicity including pancytopenia, severe mucositis, hepatotoxicity, and nephrotoxicity. Risk is highest with high-dose methotrexate but is also present with low-dose weekly methotrexate.",
      "management": "Avoid concurrent use if possible, especially with high-dose methotrexate. If combination is necessary with low-dose methotrexate (e.g., RA patients), use the lowest effective NSAID dose for the shortest duration, monitor CBC and renal function closely, and hold NSAIDs for 1-2 days before and after methotrexate dosing. Consider acetaminophen as an alternative analgesic.",
      "evidence_level": "well_established"
    },
    "int_ciprofloxacin_theophylline": {
      "interaction_id": "int_ciprofloxacin_theophylline",
      "drug_a": "ciprofloxacin",
      "drug_b": "theophylline",
      "severity": "moderate",
      "mechanism": "Ciprofloxacin is a potent inhibitor of CYP1A2, which is the primary metabolic pathway for theophylline. Inhibition of CYP1A2 leads to significantly reduced theophylline clearance (by 20-30%) and elevated serum levels. Theophylline has a narrow therapeutic index (5-15 mcg/mL), making even modest increases in levels clinically significant.",
      "effect": "Elevated theophylline serum levels with risk of toxicity: nausea, vomiting, tremor, restlessness, tachycardia. At higher levels (>20 mcg/mL): seizures, life-threatening cardiac arrhythmias.",
      "management": "Reduce theophylline dose by approximately 30-50% when initiating ciprofloxacin. Monitor theophylline serum levels within 24-48 hours of starting ciprofloxacin and adjust dose accordingly. Consider using a fluoroquinolone with less CYP1A2 inhibition (e.g., levofloxacin, moxifloxacin) or an alternative antibiotic class entirely. Readjust theophylline dose when ciprofloxacin is discontinued.",
      "evidence_level": "well_established"
    },
    "int_digoxin_amiodarone": {
      "interaction_id": "int_digoxin_amiodarone",
      "drug_a": "digoxin",
      "drug_b": "amiodarone",
      "severity": "major",
      "mechanism": "Amiodarone inhibits P-glycoprotein (P-gp) and renal tubular secretion of digoxin, reducing digoxin clearance by approximately 50%. This leads to a significant and sustained increase in digoxin serum levels. The interaction develops gradually over 1-4 weeks due to amiodarone's extremely long half-life and persists for weeks after amiodarone discontinuation.",
      "effect": "Elevated digoxin levels (often doubling), increasing the risk of digoxin toxicity: nausea, vomiting, visual disturbances (yellow-green halos), cardiac arrhythmias (bradycardia, heart block, ventricular ectopy, bidirectional VT). Can be fatal.",
      "management": "Empirically reduce digoxin dose by 50% when initiating amiodarone. Monitor digoxin serum levels closely (within 1 week, then regularly). Target digoxin level 0.5-0.9 ng/mL. Monitor ECG and clinical symptoms of toxicity. The interaction persists for weeks after amiodarone discontinuation due to its long half-life; do not rapidly increase digoxin dose after stopping amiodarone.",
      "evidence_level": "well_established"
    },
    "int_lithium_NSAIDs": {
      "interaction_id": "int_lithium_NSAIDs",
      "drug_a": "lithium",
      "drug_b": "NSAIDs",
      "severity": "major",
      "mechanism": "NSAIDs inhibit prostaglandin synthesis in the kidney, reducing renal blood flow and glomerular filtration rate. Lithium is almost entirely renally excreted, and prostaglandin-mediated renal perfusion plays a critical role in lithium clearance. NSAIDs reduce lithium renal clearance by 10-25%, leading to increased serum lithium levels. Additionally, NSAIDs promote sodium and water retention, further reducing lithium excretion (lithium and sodium share renal reabsorption pathways).",
      "effect": "Elevated lithium serum levels with risk of lithium toxicity: tremor, nausea, diarrhea, ataxia, slurred speech (levels >1.5 mEq/L); seizures, coma, permanent neurological damage, and death at higher levels (>2.5 mEq/L).",
      "management": "Avoid concurrent use if possible. If an NSAID is necessary, use the lowest effective dose for the shortest duration, reduce lithium dose prophylactically, and monitor lithium levels within 3-5 days of starting the NSAID and then regularly. Sulindac may have less effect on lithium levels (inconsistent data). Acetaminophen is the preferred analgesic alternative. Low-dose aspirin (81 mg) may be safer than full-dose NSAIDs. Educate patients to maintain adequate hydration and sodium intake.",
      "evidence_level": "well_established"
    },
    "int_rifampin_oral_contraceptives": {
      "interaction_id": "int_rifampin_oral_contraceptives",
      "drug_a": "rifampin",
      "drug_b": "oral_contraceptives",
      "severity": "moderate",
      "mechanism": "Rifampin is one of the most potent known inducers of CYP3A4 and P-glycoprotein, dramatically increasing the metabolism of both ethinyl estradiol and progestin components of oral contraceptives. Rifampin also induces intestinal P-gp, reducing absorption, and disrupts enterohepatic recirculation of estrogens. This results in substantially reduced serum levels of both contraceptive hormones, often below the threshold needed for ovulation suppression.",
      "effect": "Markedly reduced contraceptive efficacy with high risk of unintended pregnancy. Breakthrough bleeding and spotting are common clinical indicators but are not reliable markers of contraceptive failure — ovulation can occur without breakthrough bleeding.",
      "management": "Oral contraceptives should NOT be relied upon as the sole method of contraception during rifampin use. Recommend a non-hormonal contraceptive method (copper IUD, barrier methods) or depot medroxyprogesterone acetate (DMPA, which may be less affected due to higher progestin levels). Continue alternative contraception for at least 28 days after rifampin discontinuation (due to persistent enzyme induction). Higher-dose ethinyl estradiol (50 mcg) formulations are sometimes used but reliability is still uncertain.",
      "evidence_level": "well_established"
    }
  },
  "patient_profiles": {
    "DI_P001": {
      "patient_id": "DI_P001",
      "current_medications": ["warfarin", "lisinopril", "metformin"],
      "allergies": ["penicillin"],
      "conditions": ["atrial fibrillation", "type 2 diabetes", "hypertension"],
      "age": 68,
      "weight_kg": 82.0,
      "renal_function": "eGFR 55 mL/min (moderate impairment)",
      "hepatic_function": null
    },
    "DI_P002": {
      "patient_id": "DI_P002",
      "current_medications": ["fluoxetine", "lisinopril", "metformin", "simvastatin"],
      "allergies": [],
      "conditions": ["major depressive disorder", "hypertension", "type 2 diabetes", "hyperlipidemia"],
      "age": 45,
      "weight_kg": 70.0,
      "renal_function": "eGFR 90 mL/min (normal)",
      "hepatic_function": null
    },
    "DI_P003": {
      "patient_id": "DI_P003",
      "current_medications": ["warfarin", "amiodarone", "lisinopril", "spironolactone"],
      "allergies": ["sulfa drugs"],
      "conditions": ["atrial fibrillation", "heart failure (HFrEF)", "hypertension"],
      "age": 72,
      "weight_kg": 90.0,
      "renal_function": "eGFR 40 mL/min (moderate impairment)",
      "hepatic_function": "Child-Pugh A (mild)"
    },
    "DI_P004": {
      "patient_id": "DI_P004",
      "current_medications": ["clopidogrel", "omeprazole", "metformin", "lisinopril"],
      "allergies": ["aspirin"],
      "conditions": ["coronary artery disease (post-PCI/stent)", "type 2 diabetes", "GERD", "hypertension"],
      "age": 60,
      "weight_kg": 85.0,
      "renal_function": "eGFR 70 mL/min",
      "hepatic_function": null
    }
  },
  "alternatives": {
    "warfarin": [
      {
        "drug_name": "apixaban",
        "drug_class": "Direct Oral Anticoagulant (DOAC / Factor Xa inhibitor)",
        "reason": "Fewer drug-drug interactions than warfarin; no routine INR monitoring needed; predictable pharmacokinetics.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "rivaroxaban",
        "drug_class": "Direct Oral Anticoagulant (DOAC / Factor Xa inhibitor)",
        "reason": "Alternative DOAC; once-daily dosing; fewer food/drug interactions than warfarin.",
        "interaction_risk": "moderate"
      }
    ],
    "simvastatin": [
      {
        "drug_name": "rosuvastatin",
        "drug_class": "Statin (HMG-CoA reductase inhibitor)",
        "reason": "Not primarily metabolized by CYP3A4; lower interaction risk with amiodarone and other CYP3A4 inhibitors.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "pravastatin",
        "drug_class": "Statin (HMG-CoA reductase inhibitor)",
        "reason": "Minimal CYP metabolism; very low drug interaction potential.",
        "interaction_risk": "low"
      }
    ],
    "omeprazole": [
      {
        "drug_name": "pantoprazole",
        "drug_class": "Proton Pump Inhibitor (PPI)",
        "reason": "Minimal CYP2C19 inhibition; preferred PPI with clopidogrel.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "famotidine",
        "drug_class": "H2 Receptor Antagonist",
        "reason": "No CYP2C19 interaction; alternative acid suppression for patients on clopidogrel.",
        "interaction_risk": "low"
      }
    ],
    "tramadol": [
      {
        "drug_name": "acetaminophen",
        "drug_class": "Non-opioid analgesic",
        "reason": "No serotonergic activity; safe with SSRIs; appropriate for mild-moderate pain.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "morphine",
        "drug_class": "Opioid analgesic",
        "reason": "No significant serotonin reuptake inhibition; glucuronidated (minimal CYP interaction). Still carries respiratory depression risk.",
        "interaction_risk": "low"
      }
    ],
    "NSAIDs": [
      {
        "drug_name": "acetaminophen",
        "drug_class": "Non-opioid analgesic",
        "reason": "No effect on renal prostaglandins; does not impair lithium or methotrexate clearance; safe alternative for mild-moderate pain.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "celecoxib",
        "drug_class": "COX-2 selective NSAID",
        "reason": "Lower GI bleeding risk than nonselective NSAIDs, though still carries renal interaction risk with lithium and methotrexate.",
        "interaction_risk": "moderate"
      }
    ],
    "oral_contraceptives": [
      {
        "drug_name": "copper IUD",
        "drug_class": "Non-hormonal intrauterine device",
        "reason": "Not affected by CYP enzyme inducers like rifampin; highly effective long-acting contraception.",
        "interaction_risk": "low"
      },
      {
        "drug_name": "depot medroxyprogesterone acetate",
        "drug_class": "Injectable progestin contraceptive",
        "reason": "High progestin levels may partially overcome enzyme induction; more reliable than oral hormonal contraceptives with rifampin (though not fully guaranteed).",
        "interaction_risk": "moderate"
      }
    ]
  },
  "interaction_check_log": []
}
